Volume : 13, Issue : 05, May – 2026
Title:
A PROSPECTIVE OBSERVATIONAL STUDY ON THE EFFECT OF IRON THERAPY ON HAEMOGLOBIN LEVELS IN DIALYSIS PATIENTS
Authors :
Dr. Shravan R, Dr. Jeeva George, Dr. Balakeshwa Ramaiah, Dr. Shabnam Taj N P
Abstract :
Background: Anemia is a common complication of chronic kidney disease (CKD) and significantly contributes to morbidity and reduced quality of life. Iron therapy plays a central role in correcting anemia among CKD patients. This study was conducted to evaluate the hematological response and safety profile of iron therapy over four weeks in CKD patients and to compare responses across gender, age groups, and comorbidities.
Methods: A prospective observational study was conducted among 109 CKD patients. Baseline demographic, clinical, hematological, renal, electrolyte, and vital parameters were recorded and reassessed at 4 weeks. Statistical analysis was performed to determine mean differences and significance levels.
Results: Hemoglobin increased significantly from 7.9 ± 0.91 to 9.8 ± 1.65 g/dL (p<0.001). Significant improvements were also observed in hematocrit, RBC count, MCV, MCH, and MCHC. Renal parameters and vital signs showed no statistically significant changes, indicating clinical stability. Hematological improvements were consistent across gender, age groups, and comorbidities.
Conclusion: Iron therapy significantly improves anemia in CKD patients without adversely affecting renal function or hemodynamic parameters, supporting its safety and effectiveness in routine clinical practice.
Keywords : Chronic Kidney Disease; Anemia; Iron Therapy; Hemoglobin; Hematological Parameters; Intravenous Iron; Erythropoiesis; Renal Function; Comorbidities; Hemodialysis.
Cite This Article:
Please cite this article in press Jeeva George et al., A Prospective Observational Study On The Effect Of Iron Therapy On Haemoglobin Levels In Dialysis Patients., Indo Am. J. P. Sci, 2026; 13(05).
REFERENCES:
1. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA. 2019 Oct 1;322(13):1294-1304.
2. Badura K, Janc J, Wąsik J, Gnitecki S, Skwira S, Młynarska E, Rysz J, Franczyk B. Anemia of Chronic Kidney Disease—A Narrative Review of Its Pathophysiology, Diagnosis, and Management. Biomedicines. 2024; 12(6):1191.
3. Kim D, Lee J, Toyama T, Liyanage T, Woodward M, Matsushita K, Hooi LS, Lin MY, Iseki K, Jha V, Wong MG, Jun M; Asian Renal Collaboration. Prevalence and Treatment Patterns of Anaemia in Individuals With Chronic Kidney Disease Across Asia: A Systematic Review and Meta-Analysis. Nephrology (Carlton). 2025 Feb;30(2):e70002
4. Bazeley JW, Wish JB. Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review. Am J Kidney Dis. 2022 Jun;79(6):868-876.
5. Ogolla CO, Karani LW, Musyoki S, Maruti P. Impact of Iron Deficiency and Erythropoiesis-Stimulating Agents on Anemia in CKD Progression. Int J Nephrol. 2025 Sep 24;2025:2567637.
6. Lee K-H, Ho Y, Tarng D-C. Iron Therapy in Chronic Kidney Disease: Days of Future Past. International Journal of Molecular Sciences. 2021; 22(3):1008.
7. Bharti V, Katiyar DK. Comparative Study of Oral vs. Intravenous Iron Supplements in the Management of Anemia in Chronic Kidney Disease. J Neonatal Surg 2025 ;14(12S):562-7.
8. Mikhail AI, Schön S, Simon S, Brown C, Hegbrant JBA, Jensen G, Moore J, Lundberg LDI. A prospective observational study of iron isomaltoside in haemodialysis patients with chronic kidney disease treated for iron deficiency (DINO). BMC Nephrol. 2019 Jan 10;20(1):13
9. Mambatta AK, Alagesan M, Meeran M, Rein JL, Ganesan S, Mathew AC, Gurusamy V, Kuppusamy J, Menon MC. Evaluation of iron status in patients with end stage renal disease. Int J Adv Med. 2017;4(5):1415-21.
10. Gutiérrez OM. Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney Disease. Kidney Int Rep. 2021 Jun 5;6(9):2261-2269.
11. Yadav P, Narendra Varma J, Goutham Krishna K, Noufal Rizhwan H, Satheesh Kumar E, Padma L. A clinical study on single-dose intravenous iron therapy’s impact on hemoglobin and its outcomes in hospitalized chronic kidney disease patients. Indian J Pharm Pharmacol 2024;11(4):231-237
12. Bansal, Shyam & Lokkur, Pooja & Subhash, Sanat & Subbiah, Arunkumar & Sethi, Sidharth & Chellappan, Anand & Bagchi, Soumita & Doshi, Kush & Rao S, Namrata & Jeloka, Tarun & Aliaga, Joseph & Alexander, Suceena & Kumar, Vivek & Gang, Sishir & Bhadauria, Dharmendra & Meyyappan, Jeyakumar & Suresh, Sandhya & Balan, Satish & Prasad, Narayan & Jha, Vivekanand. (2025). Anemia of Chronic Kidney Disease in India: Consensus Guidelines of Indian Society of Nephrology. Indian Journal of Nephrology. 35. S1-S31.
13. Zununi Vahed S, Ahmadian E, Hejazian SM, Esmaeili S, Farnood F. The Impact of Intravenous Iron Supplementation on Hematinic Parameters and Erythropoietin Requirements in Hemodialysis Patients. Adv Ther. 2021 Aug;38(8):4413-4424.
14. Khanna U, Perugu PK, Kumar A, Sheth S, Gaikwad A, Gajbe P, Wangikar P, Suryawanshi S. AIM HD-CKD study: assessment of the efficacy and safety of ferric carboxymaltose in iron deficiency anemia management in haemodialysis patients with chronic kidney disease. Int J Clin Trials. 2025;12(2):80-6.
15. Campoverde, C., Szyferman, A.Y., Napoli, F. et al. Efficacy and safety of high-dose intravenous iron in the treatment of iron-deficiency anemia in patients undergoing hemodialysis: a systematic review and meta-analysis of randomized controlled trials. Ren Replace Ther 11, 68 (2025).
16. Adler M, Herrera-Gómez F, Martín-García D, Gavid M, Álvarez FJ, Ochoa-Sangrador C. The Impact of Iron Supplementation for Treating Anemia in Patients with Chronic Kidney Disease: Results from Pairwise and Network Meta-Analyses of Randomized Controlled Trials. Pharmaceuticals (Basel). 2020 Apr 30;13(5):85.
17. Kalra, P.A., Bhandari, S., Spyridon, M. et al. NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease. BMC Nephrol 21, 539 (2020).